biostudies-literatureDipper LStroke Associatione0304385https://www.ebi.ac.uk/biostudies/studies/S-EPMC11178191biostudies-literatureUnknown19(6)<h4>Background</h4>Stroke survivors with aphasia want to improve their everyday talking (discourse). In current UK practice, 90% of speech and language therapists believe discourse assessment and treatment is part of their role but are hampered by barriers in resources, time and expertise. There is a clinical need for well-articulated discourse assessment and treatments. LUNA is a multi-level treatment targeting words, sentences and discourse macrostructure in personal stories that addresses this clinical need.<h4>Objectives</h4>This study aimed to assess the feasibility and acceptability of LUNA trial procedures in a randomised waitlist-controlled trial; and to evaluate preliminary efficacy.<h4>Methods</h4>This paper reports a phase II, waitlist-controlled, proof-of-concept feasibility trPloS oneA feasibility randomised waitlist-controlled trial of a personalised multi-level language treatment for people with aphasia: The remote LUNA study.PMC11178191TSA2017/01Cruice MMarshall JBoyle MBarnard RBotting NDipper LHersh DCockayne LDevane NSwinburn KMagdalani CfalseA feasibility randomised waitlist-controlled trial of a personalised multi-level language treatment for people with aphasia: The remote LUNA study.<h4>Background</h4>Stroke survivors with aphasia want to improve their everyday talking (discourse). In current UK practice, 90% of speech and language therapists believe discourse assessment and treatment is part of their role but are hampered by barriers in resources, time and expertise. There is a clinical need for well-articulated discourse assessment and treatments. LUNA is a multi-level treatment targeting words, sentences and discourse macrostructure in personal stories that addresses this clinical need.<h4>Objectives</h4>This study aimed to assess the feasibility and acceptability of LUNA trial procedures in a randomised waitlist-controlled trial; and to evaluate preliminary efficacy.<h4>Methods</h4>This paper reports a phase II, waitlist-controlled, proof-of-concept feasibility tr2024-01-01T00:00:00Z20242026-06-01T21:20:46.946Z2026-05-21T03:08:19.973ZS-EPMC111781913887527910.1371/journal.pone.0304385